Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MQX-503 in Raynaud's Phenomenon
NCT00378521Phase 2Completed
- Sponsor
- MediQuest Therapeutics
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MQX-503 in Raynaud phenomenon (3 arms), sponsored by MediQuest Therapeutics. Primary endpoint: Time required for blood flow to return to baseline after cold exposure. Started Jul 2006; status: completed.
02
Drugs
MQX-503
03
Conditions
Raynaud phenomenon
Beyond the preview
Go deeper on NCT00378521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00378521.